Director/PDMR Shareholding

Summary by AI BETAClose X

GSK plc announced the vesting of a 2023 Performance Share Plan award for its Chief Financial Officer, Julie Brown, on April 27, 2026. The award saw 82% vest, with 18% lapsing, mirroring the vesting of other 2023 PSP awards. A total of 243,880 ordinary shares vested at a price of £0.00, with an additional two-year holding period required for these shares. The closing price of GSK plc ordinary shares on the vesting date was £20.16.

Disclaimer*

GSK PLC
28 April 2026
 

GSK plc (the 'Company')

Vesting of 2023 Performance Share Plan Award

This notification sets out the vesting details of a conditional share award made under the GSK 2017 Performance Share Plan ('PSP') to the Chief Financial Officer (CFO) on 27 April 2023 upon her joining GSK as CFO Designate.

Following the third anniversary of the grant, this 2023 PSP award has now vested on the same basis as the 2023 PSP awards which vested on 13 February 2026, with 82% vesting and 18% lapsed. Details of the performance measure outcomes and vesting levels are set out in the announcement of 17 February 2026.

For the CFO, the vested shares are subject to an additional two-year holding period.  

The notification that follows details the number of shares that vested under this 2023 PSP award for the CFO, including dividends accrued, on 27 April 2026. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £20.16.

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')


ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of awards granted in 2023 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

243,880






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2026-04-27

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100

Latest directors dealings